Literature DB >> 21641209

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.

Austin Chen1, Elizabeth Cauchon, Amandine Chefson, Sarah Dolman, Yves Ducharme, Daniel Dubé, Jean-Pierre Falgueyret, Pierre-André Fournier, Sébastien Gagné, Michel Gallant, Erich Grimm, Yongxin Han, Robert Houle, Jing-Qi Huang, Gregory Hughes, Hélène Jûteau, Patrick Lacombe, Sophie Lauzon, Jean-François Lévesque, Susana Liu, Dwight Macdonald, Bruce Mackay, Dan McKay, M David Percival, René St-Jacques, Sylvie Toulmond.   

Abstract

The design and optimization of a novel series of renin inhibitor is described herein. Strategically, by committing the necessary resources to the development of synthetic sequences and scaffolds that were most amenable for late stage structural diversification, even as the focus of the SAR campaign moved from one end of the molecule to another, highly potent renin inhibitors could be rapidly identified and profiled.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641209     DOI: 10.1016/j.bmcl.2011.05.014

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.

Authors:  Takeru Ehara; Osamu Irie; Takatoshi Kosaka; Takanori Kanazawa; Werner Breitenstein; Philipp Grosche; Nils Ostermann; Masaki Suzuki; Shimpei Kawakami; Kazuhide Konishi; Yuko Hitomi; Atsushi Toyao; Hiroki Gunji; Frederic Cumin; Nikolaus Schiering; Trixie Wagner; Dean F Rigel; Randy L Webb; Jürgen Maibaum; Fumiaki Yokokawa
Journal:  ACS Med Chem Lett       Date:  2014-04-21       Impact factor: 4.345

2.  A facile synthesis for novel loperamide analogs as potential μ opioid receptor agonists.

Authors:  Xiaofeng Bao; Duliang Liu; Yanyan Jin; Yao Yang
Journal:  Molecules       Date:  2012-12-03       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.